MRSN Share Price Performance
US$6.61
-29.89 (-81.89%)
94.6% undervalued intrinsic discount
US$123.29
Fair Value
Price US$6.61
AnalystConsensusTarget US$123.29
Fair ValueUS$123.29
Share PriceUS$6.61
94.6% undervalued intrinsic discount
MRSN Community Narratives
AN
Fair Value US$123.29 94.6% undervalued intrinsic discount
Emi-Le Trials And TNBC Focus Will Deliver Promise With Risk
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
Recent MRSN News & Updates
No updates
Mersana Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 13, 2025
- Earnings per share (EPS)
- -14.85
- Gross Margin
- -113.71%
- Net Profit Margin
- -217.64%
- Debt/Equity Ratio
- -66.1%
Mersana Therapeutics, Inc. Competitors
About MRSN
- Founded
- 2001
- Employees
- 102
- CEO
- WebsiteView website
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
U.S. Market Performance
- 7 Days: -0.2%
- 3 Months: 12.2%
- 1 Year: 22.4%
- Year to Date: 7.7%
The Communication Services sector gained 3.4% while the market remained flat over the last week. More promisingly, the market is up 22% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading